Cleave Biosciences Inc. has raised a $37m Series B round to fund two ongoing Phase I clinical trials for its lead drug candidate CB-5083, initiate a third trial, and to continue its hunt for therapeutic candidates that target proteins responsible for the survival of cancer cells.
Burlingame, California-based Cleave has raised $91m in venture capital during the past five years to discover and develop drugs that...





![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
